Voyager Therapeutics, Inc. (VYGR) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2024
Loading P/E history...
VYGR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Voyager Therapeutics, Inc. (VYGR) trades at a price-to-earnings ratio of -1.9x, with a stock price of $3.96 and trailing twelve-month earnings per share of $-2.04.
The current P/E is 123% below its 5-year average of 8.5x. Over the past five years, VYGR's P/E has ranged from a low of 2.7x to a high of 28.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, VYGR trades at a 109% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, VYGR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VYGR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VYGR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 43.4Lowest | -Best | +128%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
VYGR Historical P/E Data (2020–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $5.85 | $0.71 | 8.2x | -3% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $7.91 | $0.28 | 28.3x | +231% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $8.44 | $3.09 | 2.7x | -68% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $7.75 | $1.23 | 6.3x | -26% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $11.45 | $2.27 | 5.0x | -41% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $7.71 | $2.29 | 3.4x | -61% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $4.13 | $0.46 | 9.0x | +5% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $4.71 | $1.03 | 4.6x | -46% |
| FY2020 Q4 | $7.15 | $0.95 | 7.5x | -12% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $10.67 | $1.04 | 10.3x | +20% |
Average P/E for displayed period: 8.5x
See VYGR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VYGR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VYGR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVYGR — Frequently Asked Questions
Quick answers to the most common questions about buying VYGR stock.
Is VYGR stock overvalued or undervalued?
VYGR trades at -1.9x P/E, below its 5-year average of 8.5x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does VYGR's valuation compare to peers?
Voyager Therapeutics, Inc. P/E of -1.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is VYGR's PEG ratio?
VYGR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2024.